prediction
한미약품에 대해 투자의견 BUY, 목표주가 72만원(상향)을 제시했다.
A prediction by 하나증권. Statements are as reported by the cited publishers — not verified by DecisionGateway.
투자의견 BUY (괴리율 54.2%) 목표주가: 72만원 (상향)
Related claims
목표주가를 18만원에서 16만원으로 하향 조정하고 투자의견 '매수'를 유지한다.하나증권 · commitmentHanAll Biopharma is forecast to post 2027 revenue of 177.3 billion KRW, operating profit of 10.6 billion KRW, and an operating margin of 6.0%.report author · predictionMANKIND PHARMA technical pick: Buy with target 2790, potential upside ~8%.Motilal Oswal · prediction실적 추정치와 적정 밸류에이션(12MF PER 8배->7배)을 하향 조정해 목표주가를 43만원에서 36.5만원으로 하향했다.하나증권 · commitmentHanAll Biopharma is forecast to post 2026 revenue of 169.3 billion KRW, operating profit of 12.0 billion KRW, and an operating margin of 7.1%.report author · prediction삼미금속의 '26년 예상 실적은 매출 811억원(YoY+10.0%), 영업이익 86억원(YoY+48.0%, OPM 10.6%)이고, '27년 매출액은 1,000억원 이상의 성장을 기록할 전망이다.하나증권 미래산업팀 · prediction
More claims by 하나증권
The report reviewed trends and major economic indicators in the U.S. and Chinese stock markets and analyzed valuations and trends by global sector.statementThe U.S. should watch AI-related regulation and volatility in the semiconductor sector, while for China domestic demand stimulus and policy effects will be key to a sustained rebound.statementThis report is a weekly report covering global sector trends and indicators rather than a single earnings estimate for an individual company, and it does not provide annual aggregate earnings figures.statementAn approach centered on core theme ETFs such as generative AI, semiconductors, quality and cybersecurity, and on major big tech stocks, remains valid.statementAhead of Nvidia's earnings release on 11/18, market attention is focused on Blackwell demand and next-generation GPU supply outlook.statement
All claims by 하나증권